Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial

OBJECTIVES: In the phase II FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses (FORWARD) study, sprifermin demonstrated cartilage modification in the total femorotibial joint and in both femorotibial compartments by MRI in patients with knee osteoarthritis. Here, we evaluat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Rheum Dis
Main Authors: Eckstein, Felix, Kraines, Jeffrey L, Aydemir, Aida, Wirth, Wolfgang, Maschek, Susanne, Hochberg, Marc C
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2020
Assuntos:
Osteoarthritis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147175/
https://ncbi.nlm.nih.gov/pubmed/32098758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216453
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares